Company
Euclises
Clinical-stage biopharma developing oral small-molecule COX-2 drugs for cancer.
Also known as Euclises Pharmaceuticals, Inc.
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Legal name
- Euclises Pharmaceuticals, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Euclises Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company advancing the next generation of oral, small-molecule drugs that target COX-2 to disrupt the tumor microenvironment and kill cancer cells.
Funding snapshot
- Total raised
- $3.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.2M2015-11-09
Funding rounds
- Round, 2015
- $1.2M2015-11-09, SEC form D sold, 5 investors
- Round, 2013
- $1.9M2013-12-30, SEC form D sold, 9 investors
- Round, 2012
- $175K2012-05-04, SEC form D sold, 1 investor
Loading relationship preview